Spero Therapeutics price to sales ratio SPRO

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: 1.4×
8-year median: 3.5×
Against its 8-year history: 24th; percentile: 0 is its lowest day, 100 its highest
8-year range: 0.4× to 61.2×
Peer median: 1.5×

Spero Therapeutics' price to sales ratio is 1.4× as of Oct 23, 2026.

That is below its 8-year median of 3.5×, lower than on 76% of days in the last 8 years.

Over that time it ranged from 0.4× in Feb 2025 to 61.2× in Apr 2019.

The median for 8 large drugmakers of a similar size is 1.5×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.4×	1.1×	3.6×
2025	3.2×	0.4×	3.8×
2024	0.5×	0.5×	1.2×
2023	1.0×	0.8×	11.8×
2022	10.2×	1.8×	24.5×
2021	29.7×	23.7×	52.9×
2020	47.7×	6.5×	54.0×
2019	12.3×	12.1×	61.2×

Against its peers

Companies in Drug Manufacturers - General nearest Spero Therapeutics' size, closest first, today.

Company	Price to sales ratio
SPROSpero Therapeutics	1.4×
LFVNLifevantage	0.4×
ATNMActinium Pharmaceuticals	n/m
NATRNatures Sunshine Products	0.4×
ARVNArvinas	1.5×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
Peer median	1.5×

Where Spero Therapeutics ranks

#28of 157Large drugmakers with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Spero Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.